Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

Citation Tools

other Versions

You are currently viewing an earlier version of this article (February 21, 2022).
View the most recent version of this article

Commentary

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Paulino E

Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

International Journal of Gynecologic Cancer Published Online First: 21 February 2022. doi: 10.1136/ijgc-2022-003419